A man from London, Ontario, became the first patient in Canada to receive HEMGENIX gene therapy for hemophilia B [1].
This milestone represents a shift in the treatment of severe hemophilia B by introducing a curative option through public funding. By moving beyond traditional lifelong management, the therapy aims to reduce the burden of frequent clotting factor infusions for patients.
The treatment, known as etranacogene dezaparvovec, was administered on May 22, 2026 [1], [2]. This rollout marks the first time this specific gene therapy has been provided to a Canadian patient under a publicly funded model [2].
Hemophilia B is a bleeding disorder caused by a deficiency of clotting factor IX. Traditional treatments require regular injections to prevent or treat bleeding episodes. The HEMGENIX therapy is designed to provide a long-term solution by enabling the patient's own body to produce the missing factor.
CSL Canada said it administered the therapy in Ontario [2]. The patient's identity remains undisclosed, but the procedure establishes a precedent for the availability of advanced genetic medicines within the Canadian healthcare system [1].
Publicly funded access to such high-cost therapies is a critical step for patients with rare genetic diseases. The implementation of this treatment in London, Ontario, serves as the initial case for a broader rollout of the therapy across the country [1], [2].
“A man from London, Ontario, became the first patient in Canada to receive HEMGENIX gene therapy for hemophilia B.”
The introduction of publicly funded gene therapy for hemophilia B in Canada signals a transition toward curative medicine for rare genetic disorders. By integrating HEMGENIX into the public health system, Canada is addressing the financial barriers that typically limit access to one-time, high-cost genetic treatments, potentially improving long-term health outcomes for patients with severe bleeding disorders.
